+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

N

Actively Recruiting

Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
564 locations
R

Actively Recruiting

Researchers are comparing two treatments, rituximab and mosunetuzumab, for patients with follicular lymphoma that has a low tumor burden. This phase III trial aims to see which treatment better helps patients avoid disease progression or worsening over time. Both drugs are monoclonal antibodies targeting cancer cells, but it is unknown which one is more effective for this condition. Participants are randomly assigned to one of two groups. One group receives rituximab intravenously on day 1 of the first cycle, then rituximab with hyaluronidase subcutaneously on days 8, 15, and 22 of the first cycle and on day 1 of later cycles cycles repeat every 56 days for up to 5 cycles. The other group receives mosunetuzumab subcutaneously on days 1, 8, and 15 of the first cycle and day 1 of later cycles cycles repeat every 21 days for up to 8 cycles. During treatment, participants have CT or PETCT scans and blood samples collected. After treatment, participants are followed every 6 months for 5 years and then yearly up to 10 years. Researchers assess progression-free survival, overall survival, response rates, event-free survival, and treatment side effects. Specimens are also collected for future research. The total participation may last up to 10 years, including long-term monitoring for disease status and safety.

Age: 18Years +All GendersPhase 3
288 locations
E

Actively Recruiting

Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.

Age: 18Years - 50YearsAll GendersPhase 3
456 locations
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations
T

Actively Recruiting

Researchers are evaluating a text-based smoking cessation program for rural cancer survivors who smoke. This phase III trial compares an eight-week scheduled gradual reduction program paired with supportive text messages to a control intervention using an informational booklet. The study aims to assess which method better helps these patients quit smoking, with a focus on improving quality of life. The trial targets adults diagnosed with cancer within the past 10 years who currently smoke at least five cigarettes daily and live in rural areas. Participants are randomly assigned to one of two groups. One group follows a personalized eight-week gradual reduction schedule for smoking, supported by 12 weeks of cessation text messages. The other group receives the National Cancer Institutes Clearing the Air booklet to assist with quitting plans. Both groups are followed for six months after their quit date to evaluate outcomes. During the study, participants complete assessments including biochemical validation of smoking cessation up to six months post-quit date. Quality of life is measured at baseline, 30 days, and six months after quitting. Participants provide urine samples and must have texting capability on a phone to receive intervention messages. Safety and progress are monitored throughout, with the total participation lasting up to six months post-quit date.

Age: 18Years +All GendersPhase 3
224 locations
R

Actively Recruiting

Healthy Volunteer

Researchers are evaluating whether using the PAGODA algorithm to guide chemotherapy dose changes for the FOLFOX regimen reduces unplanned treatment delays in patients with digestive system cancers compared to usual care. This study focuses on cancers of the gastrointestinal tract, including esophagus, stomach, colon, rectum, and related sites, where FOLFOX chemotherapy is standard treatment. The trial compares dose adjustments made by the algorithm versus those made by clinicians based on standard assessments like blood tests and patient measurements. Participants receive FOLFOX chemotherapy involving oxaliplatin, folinic acid, and fluorouracil given intravenously. They are randomly assigned to either usual care, where clinicians decide on dose changes and delays during cycles 2 to 7, or the intervention arm, where the PAGODA algorithm guides these decisions with clinician oversight. After the treatment cycles, participants are followed up at 30 and 120 days, then annually for two years to monitor outcomes and safety. During the study, researchers track chemotherapy delays, dose changes, and safety measures such as neutropenia severity and relative dose intensity. Participants undergo regular blood tests and clinical assessments to evaluate these outcomes. The main measure is the rate of unplanned chemotherapy delays from cycles 2 to 7. Secondary measures include days spent in healthcare contact, occurrence of moderate-to-severe neutropenia, and chemotherapy dose intensity. This comprehensive monitoring continues through follow-up visits to assess the long-term impact of the dosing strategies.

Age: 18Years +All GendersPhase Not Applicable
398 locations
T

Actively Recruiting

Researchers are evaluating targeted cancer treatments directed by genetic testing for patients with locally advanced or advanced solid tumors. This ComboMATCH patient screening trial is designed to match patients with specific genetic mutations in their tumor cells to investigational combination therapies. Patients included have tumors that have spread or progressed after standard treatments, or have no standard treatment proven to extend survival. The study aims to improve treatment planning by using genetic information to assign therapies. Participants undergo tumor mutational screening using previously collected tumor samples. Eligible patients aged 18 and older with biopsiable disease may have a new biopsy before starting treatment. Those with relevant mutations are assigned to one of 20 treatment subprotocols involving various drug combinations and regimens, including oral, intravenous, and intramuscular administration. Treatments are given in repeated 28-day cycles, continuing without disease progression or unacceptable toxicity. The trial includes multiple arms and cohorts tailored to specific genetic alterations and cancer types, with some allowing crossover if disease progresses. Throughout the study, participants have tumor biopsies, blood collections, imaging tests such as CT, MRI, PET scans, and cardiac assessments like echocardiograms or MUGA scans. Bone marrow aspirations or biopsies, bone scans, and brain imaging may also be performed as clinically indicated. Researchers measure patient enrollment and treatment assignment, as well as positive treatment outcomes in defined molecular cohorts. The trial may last up to 8 years, with ongoing monitoring and optional additional biopsies at disease progression to assess treatment effects and safety.

All AgesAll GendersPhase 2
484 locations
R

Actively Recruiting

Researchers are studying treatments for women with advanced or recurrent mismatch repair protein proficient pMMR and TP53 mutated endometrial cancer. The trial compares the usual chemotherapy drugs carboplatin and paclitaxel, given with or without the immunotherapy drug pembrolizumab, to new combinations that add the antiangiogenic drug bevacizumab. The goal is to see if adding bevacizumab improves the time patients live without the cancer worsening, and overall survival. Participants are randomly assigned to one of three groups. One group receives paclitaxel, carboplatin, and pembrolizumab every 3 weeks for 6 to 10 cycles, followed by maintenance pembrolizumab every 6 weeks for up to 14 cycles. Another group receives paclitaxel, carboplatin, and bevacizumab every 3 weeks for 6 to 10 cycles, then maintenance bevacizumab every 3 weeks for up to 28 doses. The third group receives all four drugs paclitaxel, carboplatin, pembrolizumab, and bevacizumab with the same schedules as above. Throughout treatment, patients have blood and urine samples taken and undergo CT or MRI scans. After completing treatment, participants are followed for up to 5 years with regular visits every 3 months for 2 years, then every 6 months for up to 3 more years. Researchers monitor progression-free survival, overall survival, side effects, and tumor response. Safety is assessed during and up to 90 days after treatment. This long-term follow-up helps evaluate the benefits and risks of adding bevacizumab to the treatment combinations.

Age: 18Years +FEMALEPhase 3
306 locations
E

Actively Recruiting

Researchers are evaluating a combination targeted therapy called ViPOR for adults with relapsed or refractory aggressive B-cell lymphoma, including CD10-negative diffuse large B-cell lymphoma DLBCL and high-grade B-cell lymphoma with MYC and BCL2 rearrangements. This phase II trial aims to assess how well ViPOR works in these patients, focusing on complete response rates and various survival measures. The study also explores molecular factors that may affect response to treatment. Participants receive a combination of drugs venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide Revlimid. These medicines are given orally or intravenously in cycles repeating every 21 days for up to six cycles, unless the disease progresses or side effects become unacceptable. Optional procedures include tumor biopsies and bone marrow sampling, along with imaging tests like PET, CT, and MRI to monitor the disease. Throughout the study, participants undergo regular assessments including blood tests, scans, and biopsies to evaluate treatment effects and safety. After finishing treatment, they are followed up every six months for two years, then yearly for years three to five, and monitored for survival for up to ten years. Researchers measure outcomes such as complete response rates, overall response, duration of response, progression-free survival, and overall survival to determine the therapys impact.

Age: 18Years +All GendersPhase 2
114 locations